Supplemental_NNP financial_JJ information_NN Summary_NNP of_IN differences_NNS between_IN UK_NNP and_CC US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS unaudited_JJ The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT adjustments_NNS to_TO the_DT groups_NNS net_JJ income_NN and_CC shareholders_NNS equity_NN of_IN applying_VBG the_DT significant_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ._.
These_DT are_VBP summarised_VBN in_IN the_DT tabular_JJ reconciliation_NN statements_NNS set_VBN out_RP below_IN ._.
Reconciliation_NNP of_IN consolidated_JJ net_JJ income_NN Notes_NNS 12_CD months_NNS to_TO 12_CD months_NNS to_TO 31_CD Dec_NNP 2003_CD 31_CD Dec_NNP 2002_CD m_FW m_FW Profit_NN attributable_JJ to_TO shareholders_NNS reported_VBN under_IN UK_NNP GAAP_NNP 116_CD 179_CD US_NNP GAAP_NNP adjustments_NNS :_: i_FW Business_NN combinations_NNS 36_CD 114_CD iii_FW Disposal_NNP of_IN investment_NN in_IN Nycomed_NNP Pharma_NNP -_: 1_CD iv_NN Derivative_JJ hedging_NN 3_CD 66_CD v_NN Pension_NN and_CC post_NN retirement_NN costs_NNS 15_CD 5_CD vi_FW Revenue_NN recognition_NN 1_CD 1_CD vii_FW Deferred_JJ taxation_NN application_NN of_IN full_JJ liability_NN method_NN 3_CD 6_CD viii_FW Compensated_VBN absences_NNS ,_, equity_NN instruments_NNS and_CC other_JJ 7_CD -_: Tax_NNP effect_NN of_IN US_NNP GAAP_NNP adjustments_NNS 30_CD 30_CD x_SYM Minority_NNP interest_NN -_: 1_CD Total_JJ US_NNP GAAP_NNP adjustments_NNS 27_CD 18_CD Net_JJ income_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 89_CD 161_CD Basic_JJ net_JJ income_NN per_IN share_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 12.7_CD p_NN 23.4_CD p_VBP Diluted_JJ net_JJ income_NN per_IN share_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 12.6_CD p_NN 23.3_CD p_NN Reconciliation_NNP of_IN shareholders_NNS equity_NN Notes_NNP 31_CD Dec_NNP 2003_CD 31_CD Dec_NNP 2002_CD m_NN m_NN Equity_NNP shareholders_NNS funds_NNS reported_VBN under_IN UK_NNP GAAP_NNP 1,240_CD 1,172_CD US_NNP GAAP_NNP adjustments_NNS :_: i_FW Business_NN combinations_NNS 1,016_CD 1,067_CD ii_FW 41_CD Accounting_NN for_IN investment_NN in_IN NMP_NNP 42_CD iv_NN Derivative_JJ hedging_NN 25_CD 33_CD v_NN Pension_NN and_CC post_NN retirement_NN costs_NNS 46_CD 69_CD vi_FW Revenue_NN recognition_NN 3_CD 4_CD vii_FW Deferred_JJ taxation_NN application_NN of_IN full_JJ liability_NN method_NN 27_CD 28_CD viii_NN Compensated_VBN absences_NNS ,_, equity_NN instruments_NNS and_CC other_JJ 21_CD 22_CD ix_NN Ordinary_JJ dividend_NN 42_CD 36_CD Tax_NNP effect_NN of_IN US_NNP GAAP_NNP adjustments_NNS 113_CD 143_CD Total_JJ US_NNP GAAP_NNP adjustments_NNS 968_CD 968_CD Shareholders_NNS equity_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 2,208_CD 2,140_CD i_FW Business_NN combinations_NNS Under_IN both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ,_, acquisitions_NNS are_VBP accounted_VBN for_IN as_IN purchase_NN business_NN combinations_NNS ._.
However_RB ,_, certain_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP in_IN the_DT application_NN of_IN the_DT purchase_NN method_NN of_IN accounting_NN for_IN business_NN combinations_NNS are_VBP set_VBN out_RP below_IN ._.
Both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP require_VBP purchase_NN consideration_NN to_TO be_VB allocated_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN at_IN their_PRP$ fair_JJ value_NN on_IN the_DT date_NN of_IN acquisition_NN ,_, with_IN the_DT difference_NN between_IN the_DT consideration_NN and_CC the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ net_JJ assets_NNS recorded_VBN as_IN goodwill_NN ._.
Under_IN the_DT requirements_NNS of_IN Financial_NNP Reporting_NNP Standard_NNP FRS_NNP 10_CD Goodwill_NNP and_CC intangible_JJ assets_NNS ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS ,_, and_CC associates_NNS during_IN accounting_NN periods_NNS ending_VBG on_IN or_CC after_IN 23_CD December_NNP 1998_CD should_MD be_VB capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN ._.
This_DT treatment_NN of_IN goodwill_NN is_VBZ similar_JJ to_TO its_PRP$ treatment_NN under_IN US_NNP GAAP_NNP prior_RB to_TO the_DT introduction_NN of_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP 142_CD Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ._.
However_RB ,_, because_IN FRS_NNP 10_CD need_MD not_RB be_VB applied_VBN retrospectively_RB to_TO goodwill_NN written_VBN off_RP against_IN shareholders_NNS funds_NNS in_IN earlier_JJR years_NNS ,_, there_EX will_MD continue_VB to_TO be_VB differences_NNS between_IN the_DT goodwill_NN calculated_VBN under_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ._.
For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP ,_, goodwill_NN written_VBN off_RP against_IN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP has_VBZ been_VBN reinstated_VBN ._.
72_CD UK_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN purchase_NN consideration_NN to_TO intangible_JJ assets_NNS ,_, which_WDT are_VBP separable_JJ from_IN the_DT business_NN ._.
For_IN UK_NNP GAAP_NNP purposes_NNS ,_, intangible_JJ assets_NNS ,_, other_JJ than_IN goodwill_NN ,_, acquired_VBN in_IN a_DT business_NN combination_NN ,_, which_WDT are_VBP not_RB separable_JJ and_CC measurable_JJ ,_, are_VBP not_RB capitalized_VBN ._.
US_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN consideration_NN to_TO identifiable_JJ intangible_JJ assets_NNS if_IN they_PRP arise_VBP from_IN contractual_JJ or_CC other_JJ legal_JJ rights_NNS :_: if_IN intangible_JJ assets_NNS do_VBP not_RB arise_VB from_IN contractual_JJ or_CC legal_JJ rights_NNS ,_, the_DT asset_NN is_VBZ recognized_VBN apart_RB from_IN goodwill_NN only_RB if_IN it_PRP is_VBZ separable_JJ ._.
The_DT intangible_JJ assets_NNS recognized_VBN for_IN US_NNP GAAP_NNP are_VBP being_VBG amortised_VBN on_IN a_DT straight-line_JJ basis_NN over_IN periods_NNS up_IN to_TO 15_CD years_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, following_VBG the_DT introduction_NN of_IN SFAS_NNP 142_CD ,_, goodwill_NN and_CC intangible_JJ assets_NNS with_IN indefinite_JJ useful_JJ lives_NNS are_VBP not_RB amortised_VBN but_CC reviewed_VBN annually_RB for_IN impairment_NN ._.
The_DT annual_JJ goodwill_NN amortisation_NN charge_NN recognized_VBN for_IN UK_NNP GAAP_NNP has_VBZ therefore_RB been_VBN reversed_VBN for_IN US_NNP GAAP_NNP purposes_NNS ._.
Purchase_NN of_IN 45_CD %_NN minority_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS in_IN 2002_CD Under_IN UK_NNP GAAP_NNP ,_, fair_JJ value_NN adjustments_NNS have_VBP been_VBN recognized_VBN for_IN tangible_JJ fixed_JJ assets_NNS ,_, listed_VBN investments_NNS and_CC the_DT funded_JJ status_NN of_IN pensions_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, additional_JJ fair_JJ value_NN adjustments_NNS have_VBP been_VBN recognized_VBN for_IN separable_JJ intangible_JJ assets_NNS ,_, in-process_JJ research_NN and_CC development_NN and_CC the_DT revaluation_NN of_IN inventory_NN ._.
Intangible_JJ assets_NNS are_VBP being_VBG amortised_VBN on_IN a_DT straight-line_JJ basis_NN over_IN periods_NNS up_IN to_TO 10_CD years_NNS ._.
Profit_NN or_CC loss_NN on_IN the_DT partial_JJ disposal_NN of_IN businesses_NNS Under_IN UK_NNP GAAP_NNP ,_, gains_VBZ on_IN the_DT partial_JJ disposal_NN of_IN businesses_NNS involving_VBG non-monetary_JJ consideration_NN are_VBP recorded_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, when_WRB recorded_VBN in_IN connection_NN with_IN a_DT business_NN combination_NN ,_, these_DT gains_NNS and_CC losses_NNS are_VBP recorded_VBN in_IN the_DT income_NN statement_NN ._.
ii_FW Accounting_NN for_IN investment_NN in_IN Nihon_NNP Medi-Physics_NNP NMP_NNP Under_IN UK_NNP GAAP_NNP the_DT change_NN from_IN the_DT cost_NN method_NN to_TO the_DT equity_NN method_NN in_IN the_DT year_NN ended_VBD 31_CD March_NNP 1997_CD ,_, due_JJ to_TO the_DT acquisition_NN of_IN an_DT additional_JJ interest_NN in_IN NMP_NNP ,_, did_VBD not_RB require_VB retroactive_JJ adjustment_NN to_TO the_DT financial_JJ statements_NNS ._.
Under_IN US_NNP GAAP_NNP the_DT investment_NN ,_, the_DT results_NNS of_IN operations_NNS ,_, and_CC shareholders_NNS equity_NN of_IN the_DT group_NN were_VBD adjusted_VBN retroactively_RB in_IN a_DT manner_NN consistent_JJ with_IN the_DT accounting_NN for_IN a_DT step-by-step_JJ acquisition_NN of_IN a_DT subsidiary_NN ._.
iii_FW Disposal_NNP of_IN investment_NN in_IN Nycomed_NNP Pharma_NNP In_IN 2001_CD ,_, the_DT group_NN sold_VBD its_PRP$ trade_NN investment_NN in_IN Nycomed_NNP Pharma_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT investment_NN was_VBD treated_VBN as_IN an_DT associate_JJ company_NN resulting_VBG in_IN a_DT lower_JJR profit_NN on_IN disposal_NN under_IN the_DT equity_NN method_NN of_IN accounting_NN ._.
Certain_JJ costs_NNS associated_VBN with_IN the_DT sale_NN have_VBP been_VBN recognized_VBN in_IN 2002_CD for_IN US_NNP GAAP_NNP ._.
iv_NN Derivative_JJ hedging_NN Under_IN US_NNP GAAP_NNP ,_, the_DT group_NN does_VBZ not_RB qualify_VB for_IN hedge_JJ accounting_NN and_CC so_RB gains_NNS and_CC losses_NNS arising_VBG on_IN derivative_JJ instruments_NNS at_IN the_DT year_NN end_NN have_VBP been_VBN booked_VBN directly_RB to_TO income_NN ._.
v_FW Pension_NN and_CC post_NN retirement_NN costs_NNS Under_IN both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ,_, pension_NN and_CC post_NN retirement_NN costs_NNS are_VBP based_VBN on_IN actuarial_JJ assumptions_NNS ._.
However_RB ,_, under_IN UK_NNP GAAP_NNP the_DT cost_NN is_VBZ based_VBN on_IN long_JJ term_NN market_NN and_CC economic_JJ assumptions_NNS and_CC under_IN US_NNP GAAP_NNP the_DT cost_NN is_VBZ based_VBN on_IN current_JJ market_NN and_CC economic_JJ assumptions_NNS ._.
In_IN line_NN with_IN SFAS_NNP 87_CD Employers_NNP Accounting_NNP for_IN Pensions_NNP an_DT additional_JJ minimum_NN liability_NN equal_JJ to_TO the_DT unfunded_JJ accumulated_VBN benefit_NN obligation_NN is_VBZ recognized_VBN when_WRB the_DT accumulated_VBN benefit_NN obligation_NN exceeds_VBZ the_DT fair_JJ value_NN of_IN pension_NN fund_NN assets_NNS ._.
A_DT transfer_NN of_IN assets_NNS was_VBD received_VBN from_IN former_JJ pension_NN plans_NNS during_IN 2001_CD ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT proportion_NN of_IN the_DT transfer_NN relating_VBG to_TO current_JJ employees_NNS of_IN the_DT group_NN is_VBZ being_VBG spread_VBN over_IN the_DT remaining_VBG service_NN life_NN of_IN the_DT employees_NNS in_IN line_NN with_IN SSAP_NNP 24_CD ._.
Under_IN US_NNP GAAP_NNP this_DT was_VBD taken_VBN to_TO income_NN during_IN 2001_CD ._.
vi_FW Revenue_NN recognition_NN Under_IN UK_NNP GAAP_NNP ,_, contract_NN revenue_NN is_VBZ recognized_VBN when_WRB it_PRP is_VBZ earned_VBN and_CC non-refundable_JJ and_CC when_WRB there_EX are_VBP no_DT future_JJ obligations_NNS under_IN the_DT contract_NN terms_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT group_NN applies_VBZ Staff_NNP Accounting_NNP Bulletin_NNP 101_CD SAB_NNP 101_CD Revenue_NN Recognition_NN in_IN Financial_NNP Statements_NNP ._.
Under_IN SAB_NNP 101_CD ,_, more_JJR prescriptive_JJ criteria_NNS are_VBP applied_VBN to_TO assess_VB whether_IN the_DT culmination_NN of_IN the_DT earnings_NNS process_NN has_VBZ occurred_VBN and_CC the_DT group_NN has_VBZ a_DT continuing_VBG obligation_NN throughout_IN the_DT contract_NN terms_NNS ._.
As_IN a_DT result_NN ,_, certain_JJ non-refundable_JJ fees_NNS have_VBP been_VBN deferred_VBN over_IN the_DT contract_NN terms_NNS under_IN US_NNP GAAP_NNP ._.
73_CD vii_FW Deferred_JJ taxation_NN Under_IN UK_NNP GAAP_NNP ,_, provision_NN for_IN deferred_VBN taxation_NN is_VBZ recorded_VBN under_IN FRS_NNP 19_CD ._.
Except_IN for_IN certain_JJ timing_NN differences_NNS relating_VBG to_TO revaluations_NNS ,_, rolled_VBD over_IN taxable_JJ gains_NNS and_CC unremitted_JJ income_NN ,_, a_DT provision_NN is_VBZ made_VBN for_IN all_DT timing_NN differences_NNS that_WDT would_MD give_VB rise_VB to_TO a_DT deferred_VBN tax_NN liability_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB they_PRP will_MD be_VB recoverable_JJ ._.
Under_IN US_NNP GAAP_NNP ,_, deferred_VBN tax_NN is_VBZ provided_VBN for_IN on_IN a_DT full_JJ liability_NN basis_NN ,_, which_WDT includes_VBZ these_DT exceptions_NNS noted_VBD above_IN ._.
A_DT valuation_NN allowance_NN is_VBZ established_VBN when_WRB it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN some_DT portion_NN or_CC all_DT of_IN the_DT deferred_JJ tax_NN asset_NN will_MD not_RB be_VB realized_VBN ._.
viii_FW Compensated_VBN absences_NNS ,_, equity_NN instruments_NNS and_CC other_JJ Differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP relate_VBP to_TO accounting_VBG for_IN compensated_VBN absences_NNS ,_, investments_NNS in_IN equity_NN securities_NNS ,_, ESOP_NNP transactions_NNS ,_, social_JJ security_NN on_IN share_NN option_NN gains_NNS and_CC stock_NN based_VBN compensation_NN ._.
ix_FW Ordinary_NNP dividends_NNS Under_IN UK_NNP GAAP_NNP ,_, dividends_NNS proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT period_NN in_IN respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN the_DT Board_NNP of_IN Directors_NNS for_IN approval_NN by_IN the_DT shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, dividends_NNS are_VBP recorded_VBN as_IN a_DT reduction_NN to_TO retained_VBN earnings_NNS when_WRB they_PRP have_VBP been_VBN formally_RB declared_VBN ,_, and_CC notice_VB given_VBN to_TO shareholders_NNS ._.
x_LS Minority_NNP interest_NN The_DT amount_NN represents_VBZ the_DT components_NNS of_IN the_DT US_NNP GAAP_NNP adjustments_NNS attributable_JJ to_TO Pharmacia_NNP Corporations_NNS 45_CD %_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS ._.
The_DT minority_NN interest_NN was_VBD extinguished_VBN in_IN 2002_CD on_IN the_DT purchase_NN of_IN the_DT 45_CD %_NN interest_NN in_IN Amersham_NNP Biosciences_NNPS that_IN the_DT group_NN did_VBD not_RB already_RB own_VB ._.
